News
Zacks Investment Research on MSN5h
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales ViewModerna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback